Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Blood (2024) 144 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2024-201533

Published: 2024

Journal Articles

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Blood (2024) 144 (Supplement 1): 2002.

https://doi.org/10.1182/blood-2024-209232

Published: 2024

Journal Articles

Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Nieves Lopez-Muñoz, Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Seina Lee, Teresa Hernando, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J Harrison, Urvi A. Shah

Blood (2024) 144 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2024-201568

Published: 2024

Journal Articles

Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab

Irvin Yi, Eleni Gaspar, William Eighmy, Heidi Roeder, Noffar Bar

Blood (2024) 144 (Supplement 1): 7004.

https://doi.org/10.1182/blood-2024-199190

Published: 2024

Journal Articles

Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7831.

https://doi.org/10.1182/blood-2024-204150

Published: 2024

Journal Articles

Comprehensive Characterization of Coagulation Parameters in Venous Malformations

Valentina Restrepo, Alexander B Pine, Ayesha Butt, Eric Y Chang, Noffar Bar, Audrey Baluha, Andrea Brooks, Giavanna Chirico, Jeffrey Curran, Anne Dumont, Pauline Obura-Wilkes, Henry M Rinder, Christopher Tormey, Naiem Nassiri, Alfred I Lee, Stephanie Prozora

Blood (2023) 142 (Supplement 1): 27.

https://doi.org/10.1182/blood-2023-190609

Published: 2023

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

Sabrina L. Browning, Allison J. Li, Terri L. Parker, Noffar Bar, Tara Anderson, Erica Stevens, Yuxin Liu, Martin Matthews, Jennifer VanOudenhove, Rebecca Cardone, Qiushi Sun, Robert Hale, Stephanie Halene, Richard Kibbey, Natalia Neparidze

Blood (2023) 142 (Supplement 1): 4774.

https://doi.org/10.1182/blood-2023-186401

Published: 2023

Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noffar Bar, Joris Diels, Suzy van Sanden, João Mendes, Teresa Hernando, Patricia Cost, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J. Harrison, Nieves Lopez-Muñoz

Blood (2023) 142 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2023-182141

Published: 2023

Journal Articles

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Tariq Kewan, Sayeef Mirza, Alexander B Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean X Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2023) 142 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2023-187295

Published: 2023

Journal Articles

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Ramzi Hamouche, Francine M. Foss, Sayeef Mirza, Mengyang Di, Iris Isufi, Noffar Bar, Lohith Gowda, Sarah Perreault, Kenneth Roberts, Stuart Seropian, Tarsheen Sethi

Blood (2023) 142 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2023-189414

Published: 2023

Journal Articles

Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders

Sean X Gu, Patrick G Gallagher, Ayesha Butt, Vivian W Gu, Kimberly Lezon-Geyda, Vincent P Schulz, Stephanie Prozora, Alfred I Lee, Natalia Neparidze, Noffar Bar, Kelsey Martin, Jennifer Cornell, Giavanna Chirico, Raja Chakraborty, Henry M Rinder, John Hwa, Robert D Bona

Blood (2023) 142 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2023-177946

Published: 2023

Journal Articles

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Abu-Sayeef Mirza, Alexander Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer VanOudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2022) 140 (Supplement 1): 10410–10412.

https://doi.org/10.1182/blood-2022-168374

Published: 2022

Journal Articles

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Blood (2022) 140 (Supplement 1): 7086–7087.

https://doi.org/10.1182/blood-2022-168109

Published: 2022

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7308–7310.

https://doi.org/10.1182/blood-2022-166325

Published: 2022

Journal Articles

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Talib Dosani, Anna Poteraj, Terri L. Parker, Noffar Bar, Sabrina L. Browning, Elan Gorshein, Tara Anderson, Karl Insogna, Natalia Neparidze

Blood (2021) 138 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2021-147466

Published: 2021

Journal Articles

Iron Infusion Reactions: Risk Factors and Real-World Experience

Ayesha Butt, Tinatin Muradashvili, Sara Soliman, George Goshua, Adrienne Joy Burns, Noffar Bar, Kelsey Martin, Gena Borgman, Robert D. Bona, Alfred Ian Lee, Natalia Neparidze

Blood (2021) 138 (Supplement 1): 4154.

https://doi.org/10.1182/blood-2021-151048

Published: 2021

Journal Articles

Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience

Yuxin Liu, Bohm Kywe, Lake Crawford, Federico Lora, Noffar Bar, Sabrina L. Browning, Elan Gorshein, Terri L. Parker, Natalia Neparidze

Blood (2021) 138 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2021-146619

Published: 2021

Journal Articles

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Sabrina L. Browning, MD, Terri L. Parker, MD, Noffar Bar, MD, Tara Anderson, PA, Madhav V. Dhodapkar, MBBS, Stuart Seropian, MD, Alfred Ian Lee, MD PhD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Mina L. Xu, MD, Elan Gorshein, DO, JD, MPH, Ashita Talsania, MCRP, MBBS, Wajih Zaheer Kidwai, MD, David H. Witt, MD, Victor Chang, MD, Andrew Lischuk, MD, Wei Wei, MD PhD, Andrew Haims, MD, Natalia Neparidze, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-136478

Published: 2020

NARROW

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab

Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma

Comprehensive Characterization of Coagulation Parameters in Venous Malformations

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Iron Infusion Reactions: Risk Factors and Real-World Experience

Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only